CA2154368C - Applications therapeutiques de l'organogenese chimerique - Google Patents

Applications therapeutiques de l'organogenese chimerique Download PDF

Info

Publication number: CA2154368C
Authority: CA; Canada
Prior art keywords: cells; chimeric; autologous; cell culture; host
Prior art date: 1993-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002154368A

Other languages

English (en)

Other versions

CA2154368A1 (fr

Inventor

Francois A. Auger

Mahmoud Rouabhia

Louis Lafleur

Lucie Germain

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Universite Laval

Original Assignee

Universite Laval

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-21

Filing date

1993-12-21

Publication date

2007-05-29

1993-01-21 Priority claimed from US08/007,318 external-priority patent/US5610007A/en

1993-12-21 Application filed by Universite Laval filed Critical Universite Laval

1994-08-04 Publication of CA2154368A1 publication Critical patent/CA2154368A1/fr

2007-05-29 Application granted granted Critical

2007-05-29 Publication of CA2154368C publication Critical patent/CA2154368C/fr

2013-12-21 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000001225 therapeutic effect Effects 0.000 title description 4
230000005305 organ development Effects 0.000 title description 2
238000004113 cell culture Methods 0.000 claims abstract description 26
238000000034 method Methods 0.000 claims abstract description 19
230000000735 allogeneic effect Effects 0.000 claims abstract description 17
230000008569 process Effects 0.000 claims abstract description 12
238000012258 culturing Methods 0.000 claims abstract description 3
210000004027 cell Anatomy 0.000 claims description 46
210000003491 skin Anatomy 0.000 claims description 24
210000002510 keratinocyte Anatomy 0.000 claims description 21
210000001339 epidermal cell Anatomy 0.000 claims description 14
210000002919 epithelial cell Anatomy 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
230000012010 growth Effects 0.000 claims description 2
210000000981 epithelium Anatomy 0.000 abstract description 9
208000014674 injury Diseases 0.000 abstract description 8
238000000338 in vitro Methods 0.000 abstract description 7
230000008733 trauma Effects 0.000 abstract description 6
230000010261 cell growth Effects 0.000 abstract description 2
241000699670 Mus sp. Species 0.000 description 15
208000027418 Wounds and injury Diseases 0.000 description 8
238000001574 biopsy Methods 0.000 description 8
206010052428 Wound Diseases 0.000 description 7
239000006285 cell suspension Substances 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
210000002615 epidermis Anatomy 0.000 description 5
238000002054 transplantation Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
239000007943 implant Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
239000008188 pellet Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
241000283707 Capra Species 0.000 description 2
102000009024 Epidermal Growth Factor Human genes 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000001142 back Anatomy 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
238000012136 culture method Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
108010007093 dispase Proteins 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000003125 immunofluorescent labeling Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
229940099259 vaseline Drugs 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
HZCBWYNLGPIQRK-LBPRGKRZSA-N 3,3',5'-triiodo-L-thyronine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC=C1OC1=CC(I)=C(O)C(I)=C1 HZCBWYNLGPIQRK-LBPRGKRZSA-N 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
239000011547 Bouin solution Substances 0.000 description 1
241001227713 Chiron Species 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
235000015655 Crocus sativus Nutrition 0.000 description 1
244000124209 Crocus sativus Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
208000007256 Nevus Diseases 0.000 description 1
-1 OCT compound Chemical class 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
206010072170 Skin wound Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
108091006044 chimera Proteins 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
210000003981 ectoderm Anatomy 0.000 description 1
238000002283 elective surgery Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000005175 epidermal keratinocyte Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000005188 flotation Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
238000013427 histology analysis Methods 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000003716 mesoderm Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
235000013974 saffron Nutrition 0.000 description 1
239000004248 saffron Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000004894 snout Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
210000000438 stratum basale Anatomy 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
210000000437 stratum spinosum Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0629—Keratinocytes; Whole skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/16—Magnesium; Mg chelators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Dermatology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Oral & Maxillofacial Surgery (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Botany (AREA)
Chemical Kinetics & Catalysis (AREA)
Materials For Medical Uses (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA002154368A 1993-01-21 1993-12-21 Applications therapeutiques de l'organogenese chimerique Expired - Lifetime CA2154368C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/007,318		1993-01-21
US08/007,318 US5610007A (en)	1993-01-21	1993-01-21	Chimeric sheets of epithelial cells
PCT/CA1993/000546 WO1994017179A1 (fr)	1993-01-21	1993-12-21	Applications therapeutiques d'une organogenese chimerique

Publications (2)

Publication Number	Publication Date
CA2154368A1 CA2154368A1 (fr)	1994-08-04
CA2154368C true CA2154368C (fr)	2007-05-29

Family

ID=38145936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002154368A Expired - Lifetime CA2154368C (fr)	1993-01-21	1993-12-21	Applications therapeutiques de l'organogenese chimerique

Country Status (1)

Country	Link
CA (1)	CA2154368C (fr)

1993
- 1993-12-21 CA CA002154368A patent/CA2154368C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2154368A1 (fr)	1994-08-04

Legal Events

Date	Code	Title	Description
2000-12-21	EEER	Examination request
2014-02-24	MKEX	Expiry	Effective date: 20131223

Publication	Publication Date	Title
Barrandon et al.	1988	New techniques for the grafting of cultured human epidermal cells onto athymic animals
US7754481B2 (en)	2010-07-13	Keratinocytes useful for the treatment of wounds
US5866167A (en)	1999-02-02	Non-viable total keratinocyte lysate for promoting wound healing
US20020039788A1 (en)	2002-04-04	Corneal epithelial graft composites
WO2008083223A1 (fr)	2008-07-10	Procédés pour la mise en culture de cellules dermiques pour le traitement de lésions cutanées telles que des brûlures
JP2001258555A (ja)	2001-09-25	細胞および組織の三次元培養系
EP0681608B1 (fr)	2004-06-09	Applications therapeutiques d'une organogenese chimerique
US8206980B2 (en)	2012-06-26	Method for cultivation of hair follicular dermal sheath cells
Ben-Bassat et al.	1992	Structural and functional evaluation of modifications in the composite skin graft: cryopreserved dermis and cultured keratinocytes
AU2003224785A1 (en)	2003-10-20	Method for growth of human conjunctival tissue equivalents for research, clinical ocular surface transplantation and tissue engineering
US6585969B1 (en)	2003-07-01	Non-viable keratinocyte cell composition or lysate for promoting wound healing
Rouabhia et al.	1992	Optimization of murine keratinocyte culture for the production of graftable epidermal sheets
Park et al.	2004	Application of physical force is essential to enrich for epidermal stem cells in primary human keratinocyte isolation
Eisinger	1985	Regeneration of epidermis by cells grown in tissue culture
CA2154368C (fr)	2007-05-29	Applications therapeutiques de l'organogenese chimerique
AU682485C (en)	1998-04-23	Therapeutic applications of chimeric organogenesis
Hakim et al.	1994	Use of biodegradable mesh as a transport for a cultured uroepithelial graft an improved method using collagen gel
Walker-Jones et al.	1989	Model for phase III autografts of epidermal cells cultured on a collagen-proteoglycan biomatrix
Rouabhia	1997	Skin regeneration after heterologous epidermal substitute grafting
Wechselberger et al.	1998	Transplantation of autologous cultured urothelium cells onto a prefabricated capsule in rats
PARTS	0	Model for the In-Vitro Generation of Human Epidermal Autografts for Potential Use in Treatment of Sickle Cell Leg Ulcers
Lawlor et al.	1996	Epidermal cell transplantation